ML-007C-MA

Phase 2Small molecule

ML-007C-MA is one of 42 small molecule programs targeting Psychosis Associated With Alzheimer's Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Psychosis Associated With Alzheimer's DiseaseRecruiting

SchizophreniaRecruiting

Psychosis Associated With Alzheimer's DiseasePhase 2

Recruiting

SchizophreniaPhase 2

Recruiting

Competition

Competitive Landscape

174 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Resotran

Takeda

Preclinical

1 2

Inapsine

Jazz Pharmaceuticals

Preclinical

1 3

Ozempic

Novo Nordisk

Preclinical

1 4

Depakote

Ibrance

Lunesta

3 7

ML-007C-MA

MMapLight Therapeutics

Phase 2

2 8

Luvox

SSolvay Pharmaceuticals

Preclinical

1 9

Catapres

Boehringer Ingelheim

Preclinical

1 10

Rapamune

PPrism Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Psychosis Associated With Alzheimer's Disease

NCT06887192

Q1 2030

Phase 2Recruiting

Schizophrenia

NCT07459647

Clinical

Trials by Indication[1]

Schizophrenia2 trials

An Open-Label Study to Assess the Long-Term Safety, Tolerability, and Effectiveness of ML-007C-MA in Adult Participants With Schizophrenia

Recruiting·MMapLight Therapeutics·Phase 2·NCT07459647·500 enrolled

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Orally Administered ML-007C-MA in Inpatient Adult Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis

Completed·MMapLight Therapeutics·Phase 2·NCT07038876·307 enrolled

Psychosis Associated With Alzheimer's Disease2 trials

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis

Recruiting·MMapLight Therapeutics·Phase 2·NCT06887192·300 enrolled

An Open-Label Study to Assess the Long-Term Safety and Tolerability of ML007C-MA in Adult Participants With Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis

Enrolling by invitation·MMapLight Therapeutics·Phase 2·NCT07459660·210 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for ML-007C-MA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ML-007C-MA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ML-007C-MA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — MapLight Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMapLight Therapeutics

ML-007C-MA

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2030

Trials by Indication[1]

Schizophrenia2 trials

Psychosis Associated With Alzheimer's Disease2 trials

References

Drug Info

Quick Facts

Related News